1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Bajaj Healthcare Ltd

Bajaj Healthcare Ltd

313.30
INR
-11.35
(-3.50%)
6.98EPS
61.66P/E
11.83BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
74.01
78.51
82.53
74.28
104.02
117.13
147.74
237.62
246.35
234
171.36
182.59
192.98
195.25
Basic EPS, GAAP
0.71
2.72
3.04
2.84
5.5
5.91
9.14
30.11
25.87
15.59
-30.36
13.29
4.98
5.7
Free Cash Flow per Basic Share
2.44
3.44
-2.05
4.36
1.85
3.68
-0.77
-25.45
-28.49
-41.95
22.47
3.39
4.65
- -
Dividend per Share
- -
- -
- -
- -
- -
0.25
- -
0.88
0.5
1.5
1
0.93
1
- -
Book Value per Share
11.04
13.82
32.83
35.87
41.17
55.39
64.47
93.63
119.02
133.23
100.86
147.6
158.34
- -
Tangible Book Value per Share
11.04
13.82
32.83
35.87
41.17
55.39
64.47
93.63
119.02
132.73
100.2
147.15
158.04
- -
Basic Weighted Avg Shares
28
28
27
28
28
28
28
28
28
28
28
30
32
32
Sales/Revenue/Turnover
2,042
2,167
2,228
2,046
2,871
3,233
4,078
6,558
6,799
6,458
4,729
5,426
6,110
6,287
Operating Margin (%)
5.09
9.16
9.84
9.59
-9.07
10.65
11.44
18.48
15.31
14.6
10.3
10.14
12.66
12.59
Depreciation Expense
89
89
93
113
111
114
121
161
176
274
314
279
275
275
Net Income, GAAP
20
75
82
78
152
163
252
831
714
430
-838
395
158
184
Effective Tax Rate (%)
40.07
37.46
39.25
- -
33.05
32.52
30.02
30.05
20.4
18.74
- -
6.69
26.32
22.65
Profit Margin (%)
0.97
3.47
3.68
3.83
5.29
5.05
6.19
12.67
10.5
6.66
-17.72
7.28
2.58
2.92
Working Capital
-128
-52
-101
-15
85
130
308
758
762
668
386
2,668
3,162
- -
LT Debt
145
222
314
268
215
174
236
797
663
944
391
649
602
- -
Total Equity
313
388
886
990
1,136
1,529
1,779
2,584
3,285
3,677
2,784
4,662
5,330
- -
Return on Invested Capital (%)
6.05
11.5
9.39
- -
-9.62
10.9
12.67
24.02
15.9
11.01
- -
8.3
4.48
- -
Return on Capital (%)
6.25
11.91
8.93
- -
10.75
9.73
11.89
25.12
15.64
8.24
- -
9.68
4.28
- -
Return on Common Equity (%)
6.84
22.39
13.02
8.34
14.29
12.24
15.26
38.09
24.33
12.36
-25.94
10.61
3.16
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
1,889
- -
LT Borrowings
- -
476
- -
LT Finance Leases
- -
126
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
32
34
34
Market Capitalization
13,110
9,766
11,831

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
6,390
- -
Cash, Cash Equivalents & STI
- -
391
- -
Accounts Receivable, Net
- -
2,339
- -
Inventories
- -
2,160
- -
Total Current Liabilities
- -
3,228
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,889
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.92%
19.31%
14.34%
Free Cash Flow
269.35%
-26.39%
46.12%
Net Income, GAAP
-17.49%
-111.16%
-60.08%
Sales/Revenue/Turnover
13.1%
-0.15%
12.61%
Total Cash Common Dividend
- -
- -
14.44%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1,322
1,331
1,228
1,545
5,426
2026
1,488
- -
1,612
1,531
6,110
2027
1,656
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2.59
3.36
3.65
3.54
13.29
2026
3.74
- -
4.96
-7.16
4.98
2027
4.07
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
0.93
2026
- -
- -
- -
- -
1
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Sajankumar R. Bajaj
Full Time Employees
1,019
Sector
Health technology
Industry
Pharmaceuticals: major
Address
602-606, Bhoomi Velocity Infotech Park Thane MH India 400604
IPO Date
May 10, 2016
Website
bajajhealth.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Bajaj Healthcare Limited (BAJAJHCARE.NS), incorporated in 1993 and headquartered in Thane, Maharashtra, India, manufactures active pharmaceutical ingredients (APIs), intermediates, finished dosage formulations (FDFs), and nutraceutical products for pharmaceutical, nutraceutical, and food industries worldwide. The company produces a diverse range of APIs including chlorhexidine and its derivatives, fosfomycin salts (calcium, sodium, trometamol), carbamazepine, oxcarbazepine, deferasirox, citicoline sodium, ascorbic palmitate, octenidine dihydrochloride, hesperidin, and diosmin; intermediates essential for API and FDF processes; FDFs such as tablets, capsules, powders, and sachets; and nutritional supplements like amino acids; with manufacturing facilities across Gujarat and Maharashtra, including 15 API plants certified under USFDA, EU-GMP, KFDA, WHO-GMP, and others, enabling exports to over 60 countries primarily in the US, Europe, Africa, and Australia. Bajaj Healthcare operates as India's largest producer of ascorbic acid and the world's largest manufacturer of chlorhexidine base, while serving as the sole private entity processing opium gum and poppy straw under government contracts, with a new facility handling 250 MT opium gum and 2,500 MT poppy straw annually. In recent developments, the company acquired GenRx Pharmaceuticals Private Limited for ₹10.85 crore in April 2025 to expand formulations manufacturing capabilities at a WHO-GMP-certified facility in Nashik producing tablets, capsules, and nasal sprays, subject to regulatory approvals expected within 3-6 months; signed definitive CDMO agreements with UK and EU customers for exclusive development and supply of 15 APIs; launched new molecules in nutraceuticals, APIs, and formulations; filed 41 DMFs in FY24; and sold a Tarapur plant to reduce debt, anticipating further asset sales by late FY25 to bolster financial position amid market challenges.